Table 2.
Human B7x expression in cancer
| Tumour | Positive B7x expression | References |
| Lung cancer | 69% (128/185) and 68% in discovery and validation cohort | 29 |
| Pancreatic cancer | 92% (33/36) in tumour samples 20% (1/5) in tumour-negative samples |
20 |
| 61.9% (39/63) in pancreatic tumour samples | 40 | |
| HCC | HBV related: HCC: 68.67% (57/83) | 41 |
| 93 HCC cases: mean sB7x: 49 ng/mL versus 31.66 ng/mL in healthy volunteers | 42 | |
| Breast cancer | 95.4% (165/173) primary breast cancer 97.6% (240/246) metastatic breast cancer |
14 |
| Gastric cancer | 25.8% (31/120) | 43 |
| 71% (71/100) | 44 | |
| Renal cancer | 59.1% (153/259) in tumours 81.5% in RCC endothelium versus 6.5% in normal tissue vessels |
13 |
| RCC sB7x concentration of 14.4 ng/mL versus 2.7 ng/mL in healthy volunteers | 13 | |
| Thyroid | 95.3% (61/64) | 45 |
| Glioma | Not reported | 24 |
| Prostate cancer | 99% (805/814); 15% with strong intensity | 12 |
| Melanoma | 96.5% (28/29) primary tumours 89.7% (26/29) metastatic tumours |
15 |
| Ovarian cancer | 100% in all 103 samples | 46 |
| Urothelial cancer | 75.8% (42/67) | 47 |
HBV, Hepatitis B virus; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma.